BBT002

Phase 1Small molecule

BBT002 is one of 45 small molecule programs targeting Chronic Obstructive Pulmonary Disease. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Chronic Obstructive Pulmonary DiseaseRecruiting

Chronic Rhinosinusitis With Nasal Polyps (crswnp)Recruiting

Chronic Obstructive Pulmonary Disease (COPD)Recruiting

Chronic Obstructive Pulmonary DiseasePhase 1

Recruiting

Chronic Rhinosinusitis With Nasal Polyps (crswnp)Preclinical

Recruiting

Chronic Obstructive Pulmonary Disease (COPD)Phase 1

Recruiting

Competition

Competitive Landscape

119 competitors in Chronic Obstructive Pulmonary Disease

#DrugCompanyPhaseTrials

Lunsekimig

Sanofi

Phase 3

3 2

CM310

KKeymed Biosciences Co.Ltd

Phase 3

1 3

Astegolimab

Roche

Phase 3

2 4

Tozorakimab

AstraZeneca

Phase 3

2 5

Avinza

HHikma Pharmaceuticals LLC

Phase 2

1 6

HSK39004

Haisco Pharmaceutical Group Co., Ltd.

Phase 2

2 7

Calciferol

Duragesic

2 9

Verekitug

UUpstream Bio Inc.

Phase 2

1 10

Narcan

SScienture

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2027

Phase 1Recruiting

Chronic Obstructive Pulmonary Disease (COPD)

NCT07288554

Q3 2027

Phase 1Recruiting

Chronic Obstructive Pulmonary Disease

NCT06944925

Q2 2028

PreclinicalRecruiting

Chronic Rhinosinusitis With Nasal Polyps (crswnp)

NCT07436949

Clinical

Trials by Indication[1]

Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)1 trial

A Randomized, Double-Blind, Placebo-controlled, Single- and Multiple-ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics,Immunogenicity, Pharmacodynamics and Clinical Activity of BBT002 in Healthy Volunteers and Participants With Chronic Rhinosinusitis With Nasal Polyps (CRSwNP) With or Without Comorbid Asthma

Recruiting·BBambusa Therapeutics·Preclinical·NCT07436949·64 enrolled

Chronic Obstructive Pulmonary Disease (COPD)1 trial

A Randomized, Double-Blind, Placebo-controlled, Single- and Multiple-ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, Pharmacodynamics and Clinical Activity of BBT002 in Healthy Volunteers and Participants With Chronic Obstructive Pulmonary Disease (COPD)

Recruiting·BBambusa Therapeutics·Phase 1·NCT07288554·68 enrolled

Chronic Obstructive Pulmonary Disease1 trial

A Randomized, Double-Blind, Placebo-controlled, Single- and Multiple-ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, Pharmacodynamics and Clinical Activity of BBT002 in Healthy Volunteers and Patients With COPD or CRSwNP

Recruiting·BBambusa Therapeutics·Phase 1·NCT06944925·286 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for BBT002. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — BBT002 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for BBT002. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Bambusa Therapeutics company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: BBambusa Therapeutics

BBT002

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2027

Q3 2027

Q2 2028

Trials by Indication[1]

Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)1 trial

Chronic Obstructive Pulmonary Disease (COPD)1 trial

Chronic Obstructive Pulmonary Disease1 trial

References

Drug Info

Quick Facts

Related News